Cooperative Agreement U01DA047791

This $395,566 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of a novel FDA-regulated pharmacotherapy as the core of a multimodal platform for smoking cessation and nicotine de-addiction. The award aims to address the significant unmet clinical need for more effective smoking cessation therapies, as existing FDA-approved treatments have limited efficacy. The proposed work will span...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $320,000 to Spacerx LLC to develop an innovative smoking/vaping cessation treatment. The goal is to explore the feasibility of delivering the smoking cessation drug cytisine through electronic vape administration (EVA) to help individuals addicted to e-cigarettes or smoking. The primary hypothesis is that EVA cytisine will stabilize...

The National Institute on Drug Abuse (NIDA) awarded a $2,187,775 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Northeastern University to develop and validate novel positive allosteric modulators (PAMs) that selectively target the high sensitivity α4β2 nicotinic acetylcholine receptor (nAChR) subtypes. The goal is to better understand the pharmacological effects of α4β2 nAChRs in behaviors characteristic of nicotine addiction, which may lead to future...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,875 to the University of California, Los Angeles (UCLA) to conduct a randomized, double-blind, crossover human laboratory study on the use of delta-9-tetrahydrocannabivarin (D9-THCV) as a potential treatment for nicotine dependence and smoking cessation. The study will enroll 32 daily smokers to assess the ability of D9-THCV to: (a)...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,230 in funding to Rafias LLC to advance NR4A1 as a novel target for treating cocaine use disorder. The objectives are to: (1) Identify lead NR4A1-activating compounds through synthesis and screening of Cytosporone B derivatives, and (2) Characterize the lead compound(s) using binding assays, synthetic feasibility, and pharmacokinetics. This...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $399,891 to Sensewhy, Inc. to develop and evaluate a system for remote monitoring of smoking behavior and intervention among cancer survivors. The key products or services to be delivered include: Feasibility evaluation of the "Smokemon" wearable device to detect and measure smoking topography (physical characteristics of smoking behavior) in...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The research aims to screen and evaluate next-generation inhibitors of the metabolic enzyme ACSS2, which has been shown to play a key role in the consolidation of drug-related memories and neuroplasticity. This project...

This $13,718,085 Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of PF614-MPAR, an opioid analgesic with built-in abuse-deterrent and overdose protection features. The key product being developed is PF614-MPAR, a combination product comprising the TAAP-oxycodone prodrug PF614 and the trypsin inhibitor nafamostat. This novel formulation is designed to provide pain...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,287,052 to Virogenomics Biodevelopment, Inc. to advance the development of the CD74-targeting compound DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The key objectives of this project are to conduct IND-enabling studies and a Phase I clinical trial to evaluate the safety of DRHQ in both...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development of a novel CB1 antagonist, ANEB-001, for the treatment of acute cannabinoid intoxication (ACI) and cannabis hyperemesis syndrome (CHS). The project, with a total funding of $892,290.00 over 2 years, will investigate the safety, pharmacokinetics, and therapeutic potential of an intravenous formulation of ANEB-001 in...